Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24

Area of Science:

• Virology
• Oncology
• Molecular Biology

Background:

• Neuroblastoma is a prevalent childhood cancer with poor survival rates, necessitating novel therapeutic strategies.
• Zika virus, an emerging flavivirus, targets neuronal progenitor cells and has shown responsiveness in neuroblastoma.
• Investigating oncolytic viruses like Zika offers potential for new cancer treatments.

Purpose of the Study:

• To assess the oncolytic potential of Zika virus as a therapy for neuroblastoma.
• To identify host cell factors influencing Zika virus permissiveness in neuroblastoma cells.
• To explore CD24 glycoprotein's role in Zika virus infection and its therapeutic implications.

Main Methods:

• Neuroblastoma cell lines were infected with Zika virus to evaluate permissiveness, viral replication, and cytopathic effects (CPE).
• Comparative analysis of highly permissive versus poorly permissive neuroblastoma cells identified differences in cell surface glycoprotein CD24 expression.
• CD24 expression was complemented in poorly permissive cells to assess its impact on Zika virus infection.

Main Results:

• Neuroblastoma cells were generally permissive to Zika virus, exhibiting significant CPE and high viral titers.
• A subset of neuroblastoma cells showed poor permissiveness, with undetectable non-structural protein 1 (NS1) and limited CPE.
• Loss of CD24 expression correlated with poor Zika virus permissiveness; restoring CD24 rescued NS1 expression, viral titers, and CPE.

Conclusions:

• CD24 glycoprotein plays a crucial role in mediating Zika virus entry and replication in neuroblastoma cells, suggesting it as a potential therapeutic target.
• Zika virus demonstrates oncolytic potential against neuroblastoma, offering a promising adjunctive therapy to target recurrent disease and treatment failures.